The Role of Factor Inhibiting HIF (FIH-1) in Inhibiting HIF-1 Transcriptional Activity in Glioblastoma Multiforme

Enfeng Wang1, Chunyang Zhang2, Navatha Polavaram3, Fengming Liu4, Gang Wu1*, Mark A. Schroeder5, Julie S. Lau1, Debabrata Mukhopadhyay1, Shi-Wen Jiang6,7, Brian Patrick O’Neill1, Kaustubh Datta3, Jinping Li6,7*

1 Department of Biochemistry and Molecular Biology, Mayo Clinic Cancer Center, Rochester, Minnesota, United States of America, 2 Department of Neuro-Surgery, the First Affiliated Hospital of Baotou Medical College, Baotou, China, 3 Department of Biochemistry and Molecular Biology and Eppley Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska, United States of America, 4 Department of Research and Development, Guangxi Medicinal Botanical Institute, Nanning, Guangxi, China, 5 Department of Radiation Oncology, Mayo Clinic Cancer Center, Rochester, Minnesota, United States of America, 6 Department of Biomedical Science, Guangxi Medicinal Botanical Institute, Nanning, Guangxi, China, 7 Department of Obstetrics and Gynecology, Memorial Health Hospital, Savannah, Georgia, United States of America

Abstract

Glioblastoma multiforme (GBM) accounts for about 38% of primary brain tumors in the United States. GBM is characterized by extensive angiogenesis (induced by vascular growth factors and cytokines). The transcription of these growth factors and cytokines is regulated by the Hypoxia Inducible Factor-1 (HIF-1), which is a key regulator mediating the cellular response to hypoxia. It is known that Factor Inhibiting HIF-1, or FIH-1, is also involved in the cellular response to hypoxia and has the capability to physically interact with HIF-1 and block its transcriptional activity under normoxic conditions. Delineation of the regulatory role of FIH-1 will help us to better understand the molecular mechanism responsible for tumor growth and progression and may lead to the design of new therapies targeting cellular pathways in response to hypoxia. Previous studies have shown that the chromosomal region of 10q24 containing the FIH-1 gene is often deleted in GBM, suggesting a role for the FIH-1 in GBM tumorigenesis and progression. In the current study, we found that FIH-1 is able to inhibit HIF-mediated transcription of GLUT1 and VEGF-A, even under hypoxic conditions in human glioblastoma cells. FIH-1 has been found to be more potent in inhibiting HIF function than PTEN. This observation points to the possibility that deletion of 10q23-24 and loss or decreased expression of FIH-1 gene may lead to a constitutive activation of HIF-1 activity, an alteration of HIF-1 targets such as GLUT1 and VEGF-A, and may contribute to the survival of cancer cells in hypoxia and the development of hypervascularization observed in GBM. Therefore FIH-1 can be potential therapeutic target for the treatment of GBM patients with poor prognosis.

Introduction

The transcription factor Hypoxia Inducible Factor-1/2 (HIF-1/2α) regulates and coordinates the expression of an extensive array of genes required to maintain oxygen homeostasis in every living system during conditions of severe oxygen stress [1–3]. Inhibiting HIF-1α function in the tumor microenvironment is important for suppressing tumor angiogenesis and increasing tumor cell apoptosis [4]. Of particular importance, a HIF-1α inhibitor, 2-methoxyestradiol, showed a dose-dependent decrease in tumor growth and angiogenesis in a rat orthotopic brain tumor model, underscoring the importance of inhibiting HIF in Glioblastoma multiforme (GBM) [5]. GBM is a highly proliferative and infiltrating primary brain tumor that contains regions of hypervascularization (angiogenesis) [6–8]. Because surgery, radiation, and chemotherapy have been unsuccessful in treating malignant gliomas [9–11], it is critically important to develop new therapeutic regimens for use along with the established treatment options. Structurally, HIF-1 is a heterodimer of two basic helix-loop-helix PAS domain proteins, namely HIF-1α and HIF-1β [12,13]. The HIF-1β subunit is constitutively detected in the nucleus, whereas the protein stability of the HIF-1α subunit and its isoforms (HIF-2α and HIF-3α) depends upon the cellular oxygen concentration [12,14,15]. In normoxic condition, the ubiquitin-proteasome pathway rapidly degrades HIF-1α subunits whose steady state levels are low, and as a result the transcriptionally active complex cannot form [16–20]. Detailed molecular studies demonstrated that in high oxygen concentrations, HIF-1α is...
hydroxylated at the proline residue of its oxygen-dependent degradation domain [21–23]. This post-translational modification of HIF-1α is necessary for degradation by the proteasome complex [17,24].

Stabilization of HIF-1α protein levels is not sufficient for the transcriptional activation of its target genes. In oxygenated cells, HIF-1α is also hydroxylated at an asparagine residue at the COOH-terminal transactivation domain (CAD). As a result, the HIF complex cannot bind to the adaptor protein p300 to execute its transcriptional activity under normoxic conditions [25–30]. In this regard, the status of Factor Inhibiting HIF-1 (FIH-1) may be important in HIF-mediated gene transcription in glioblastoma. FIH-1, presently identified as an asparagine hydroxylase [29,31,32], specifically hydroxylates the transcription factor Hypoxia Inducible Factor-1/2α (HIF-1/2α) under normal physiological conditions and inhibits its association with the adaptor protein p300 [28,33,34]. FIH-1 protein is widely expressed in human tissues and is thus potentially available for the regulation of HIF activity across a broad range of cells and culture conditions [35]. It is also suggested that FIH-1 has important non-redundant effects in vivo on the expression of a range of HIF transcriptional targets in normoxia and even in hypoxia [35]. Importantly, FIH-1 is located at chromosome 10q24, which is often deleted in glioblastoma, especially in secondary glioblastoma, making it an important candidate gene to study the progression of this cancer [36–41], while mutation of PTEN at 10q23.3 are common (12–40%) in primary glioblastoma [40,42–44]. Due to these reported details regarding FIH-1, we seek to determine the importance of the FIH-1 gene in GBM progression. Our search in ONCOMINE database also showed a significant reduction of FIH-1 mRNA levels in GBM compared to normal brain tissues (figure S1) [45]. This prompted us to further examine if the loss or decreased expression of FIH-1 played any role in HIF-mediated gene expression in GBM. We also compared the function of FIH-1 with that of PTEN in the synthesis of HIF-regulated genes including GLUT-1 and VEGF-A. Our studies clearly emphasize the importance of FIH-1 in regulating HIF-mediated genes in a subset of primary glioblastoma cases without PTEN mutation.

Materials and Methods

Cell Culture

The human glioblastoma cell line U87 MG (ATCC # HTB-14) and the serially transplanted GBM cell lines (developed at the Mayo Clinic) [46] were cultured at 37°C in RPMI 1640 with L-glutamine (Mediatech) supplemented with penicillin/streptomycin (Mediatech) and 10% normal fetal bovine serum (FBS) (Hyclone Laboratories). Cell pellets or whole cell extracts were used for Western blots, antibodies against HIF-1α, p300 (Santa Cruz Biotechnology, Santa Cruz, CA), FIH-1 (Novus Biologicals), and PTEN (Cell Signaling Technology, Denver, MA) were used.

RNA Isolation and Real-Time Polymerase Chain Reaction

After washing twice with ice cold PBS, total RNA was isolated from U87 MG and GBM lines using the RNeasy Mini kit (Qiagen). mRNA levels of GLUT-1, VEGF-A, FIH-1 were measured with Taqman real-time PCR method. The sequence for forward, reverse, and Taqman middle primers for human GLUT-1, VEGF-A, FIH-1 and for human 36B4 (housekeeping gene) were taken from the PubMed gene bank and synthesized (Integrated DNA Technologies).

GLUT-1 forward: 5'-GGG GAA TTC ATT CTT GAT GAT-3'. GLUT-1 reverse: 5'-CAG TTT CGA GAA GCC CAT GAG-3'. GLUT-1 middle primer: 5'-CT GCC CTT GCT GTC CGC CTG-3'.

VEGF-A forward: 5'-TAC TTC CAC CAT GCC AAG TG-3'. VEGF-A reverse: 5'-GAT TCT GCC CTC CTG TT-3'. VEGF-A middle primer: 5'-TCC GAC GGT GCC CCC ATG GC-3'. FIH-1 forward primer: 5'-GGC ACC CCC AAG TTC TT-3'. FIH-1 reverse primer: 5'-CCT GGG CCT CGG CTT AA-3'. FIH-1 middle primer: 5'-GTT CGG GAT AGT CCT TT-3'. FIH-1 middle primer: 5'-CT GCC CTT GCT GTC CGC CGT-3'.

Immunoprecipitation and Western Blot Analysis

Immunoprecipitation was performed with 30 μg of nuclear protein extracts or whole cell extracts using antibodies (1 μg) directed against HIF-1α or p300 and then pulled down with Protein A-agarose beads (Pharmacia, New York, NY). For Western blots, antibodies against HIF-1α (Novus Biologicals, Littleton, CO) and p300 (Santa Cruz Biotechnology, Santa Cruz, CA), FIH-1 (Novus Biologicals), and PTEN (Cell Signaling Technology, Denver, MA) were used.

FACS analysis

U87 cells were washed twice with PBS and incubated with 4 ml of collagenase solution (0.2 μg/ml collagenase, 0.2 μg/ml soybean trypsin inhibitor, 1 μg/ml BSA, and 2 mM EDTA in PBS) at 37°C for 30 min. Cells were then detached with gentle scraping and collected by centrifugation at 1100 rpm for 3 min. Cell pellets were washed twice with cold PBS containing 0.1% BSA and resuspended in the same buffer at 0.5×10⁶ cells/ml. 200 μl of the cell suspension containing 1 μg of mouse anti-GLUT-1 antibody (R&D Systems, Minneapolis, MN) or mouse IgG and incubated at 4°C for 1 hour. Cells were centrifuged at 1300 rpm for 3 min. Cell pellets were again washed twice and resuspended in 100 μl of the PBS solution containing 2.5 μg/ml fluorescein isothiocyanate-conjugated anti-mouse IgG antibody. After incubation at 4°C for 30 min, cells were washed twice and resuspended in 400 μl of the PBS solution. FACS analysis was carried out using a FACSCalibur flow cytometer (BD Biosciences) and the CellQuest software.

Nuclear Extract Preparation

The glioblastoma cell suspensions were incubated in a hypertonic buffer [10 mM HEPES (pH 7.8), 10 mM KCl, 2 mM MgCl₂, 0.1 mM EDTA, 10 μg/ml aprotinin, 3 mM dithiothreitol, and 0.2 mM phenylmethylsulfonylfluoride (PMSF)] for 15 min on ice. The nonionic detergent IGEPAL (Sigma) (10%) was then added to the cell suspensions followed by vigorous mixing. After centrifugation at 14,000 rpm for 5 min, the pellets were resuspended in a hypertonic buffer solution: 50 mM HEPES (pH 7.8), 50 mM KCl, 300 mM NaCl, 0.1 mM EDTA, 10 μg/ml aprotinin, 3 mM dithiothreitol, and 0.2 mM phenylmethylsulfonylfluoride (PMSF) and mixed on a rotating rack for 25 min at 4°C. The samples were again centrifuged at 14,000 rpm for 10 min, and the supernatants were collected as nuclear extracts.
60°C for 1 min were performed with an ABI Prism 7700 Sequence Detector (Applied Biosystems). All experiments were performed three times, and, from each of the three, triplicate readings were taken and the average was calculated. The relative RNA amount was calculated as follows: \[ \Delta = CT \text{ (GLUT-1/VEGF-A sample)} - CT \text{ (36B4 sample)} - \Delta \text{ (empty vector sample)} \]. Relative RNA amount in comparison to the control = \( 2^{-\Delta\Delta} \). The average and standard deviation from three experiments were also calculated. p value was calculated with t-test, * represents p value is less than 0.05.

Immunohistochemistry staining

Tissue sections were prepared by Drs. C. David James and Jann Sarkaria’s group at Mayo Clinic [46,50]. An immunohistochemistry accessory kit (Bethyl laboratories, Inc., Montgomery, TX) was used to examine expression levels of FIH-1 according to the manufacturer’s protocol. Briefly, after deparaffinization and rehydration, the slides were incubated in 3% hydrogen peroxide/methanol to quench endogenous peroxidase. Slides were then incubated in hot Epitope retrieval buffer (provided in kit) to recover epitopes for 20 min at 90–96°C. Non-specific reactions were blocked by incubating the sections with blocking reagent (included in the kit) for 30 min at room temperature, then 200 μl of human FIH-1 antibody (dilution 1:200, catalog ab92498, Abcam, Cambridge, MA) was applied to each slide and incubated overnight at 4°C. Slides were then incubated with working anti-rabbit IHC antibody (provided in kit), and peroxidase activity was visualized with working 3',3'-diaminobenzidine (DAB) substrate (provided in kit). Counterstaining was performed with hematoxylin. The stained sections were randomly selected high-power fields (×40).

Results

FIH-1 decreases GLUT-1 mRNA levels and thus protein levels in U87 under normoxia and hypoxia

U87 cell line, were chosen for its tolerance to the transient transfection manipulation in this study although it expresses minimal basal levels of FIH-1. U87 cells were transfected with plasmid expressing FIH-1 under normoxic and hypoxic conditions, and expression of GLUT-1 was examined. First, we observed a decrease in the level of GLUT-1 mRNA, the HIF-1α

Figure 1. The mRNA levels of GLUT-1 were reduced with FIH-1 overexpression. 1A and 1B: U87 cells were transfected with FIH-1-expression plasmid and cultured in both hypoxic (1B) and normoxic (1A) conditions. Total RNA was harvested and RQ-PCR was performed using primers specific for GLUT-1 and 36B4 (internal control). A significant decrease of GLUT-1 mRNA levels was observed in cells transfected with FIH-1 expression plasmid in both normoxia and hypoxia. The data here is the mean from three independent results. * Represents p value less than 0.05. 1C and 1D: The expression levels of GLUT-1 were decreased by overexpression of FIH-1 in U87 cells. U87 cells were transfected with constructs either expressing FIH-1 or with vector alone and incubated for 48 hrs under normoxic condition. Cells were collected and subjected to flow cytometry analysis. A reduction in GLUT-1 levels was detected in cells transfected with FIH-1 plasmid (1D) compared with cells transfected with control vector (1C), as shown in the P3 population.

doi:10.1371/journal.pone.0086102.g001
target gene \[3,6\], in U87 cells after overexpressing FIH-1 (Figure 1A). Interestingly, we also observed a decrease in the level of GLUT-1 mRNA even under hypoxic conditions, demonstrating that FIH-1 regulates HIF activity in U87 cells even in hypoxia (Figure 1B), which suggests that hypoxia is not the sole factor for inducing HIF-regulated genes in GBM \[6\] and FIH-1 involved (mediated) HIF activity regulation may also play role during GBM tumor progression in certain advanced cases. This decrease in GLUT-1 mRNA levels corresponds with decreased GLUT-1 protein levels, as observed by FACS analysis (Figure 1C and 1D).

### PTEN cannot inhibit GLUT-1 transcription in U87 under hypoxia

PTEN has been shown to be functionally inactive in many primary GBM cell lines \[40,42–44,51,52\]. Several reports have suggested that the antiangiogenic function of PTEN is due to its inhibitory role within the PI3K-AKT signaling pathway \[53\]. Because this pathway has been found to be important for HIF-1a synthesis in various cancers \[54\], we wanted to study the effect of PTEN in combination with FIH-1 on HIF activity in GBM cell line-U87-MG. We observed a decrease in the level of GLUT-1 mRNA in U87 cells when overexpressing PTEN under normoxic conditions (Figure 2A). This decrease in GLUT-1 mRNA was almost comparable to that of U87 cells overexpressing FIH-1. However, we did not observe any synergistic effects on the level of GLUT-1 mRNA when both FIH-1 and PTEN were overexpressed under normoxic conditions. Interestingly, in hypoxia, FIH-1 overexpression in U87 showed a significant decrease in GLUT-1 mRNA, but the overexpression of PTEN alone was not sufficient to decrease GLUT-1 mRNA (Figure 2A). This result therefore suggests a more potent FIH-1 function as compared to PTEN in regulating HIF activity in glioblastoma, especially under hypoxic conditions. Figure 2B shows the amount of FIH-1 and PTEN proteins in U87 cells after transfection with the FIH-1 and PTEN overexpressing plasmids.

In order to provide a mechanistic explanation for the result described in Figure 2A, we studied the association of HIF-1a with p300 in U87 cells in the presence of FIH-1, PTEN, or both under normoxic as well as hypoxic conditions (Figure 3B). The association of HIF-1a with p300 is essential for HIF-1 transcriptional activity. We observed a detectable amount of HIF-1a protein in U87 under normoxia (Figure 3A, bottom panel), and we also observed an increase in the association of HIF-1a with p300 under the same conditions (Figure 3B). This suggests that residual HIF-1 activity exists in this cancer cell line even under normoxic conditions. As in hypoxia, the U87 cells expressed high levels of HIF-1a (Figure 3B, bottom panel), and we also observed an increase in the association of HIF-1a with p300 (Figure 3B), which confirms the high HIF-1 activity under these conditions (Figure 2A). Interestingly, overexpression of FIH-1, but not PTEN, inhibited HIF-1 activity by preventing the association of p300 with HIF-1a (Figure 3B). The amount of p300 immunoprecipitated was same in each condition.

---

**Figure 2. Inhibit GLUT-1 transcription by FIH-1 in U87 under hypoxia**

GLUT-1 expression was inhibited by PTEN under normoxic condition. U87 cells were transfected with FIH-1 and PTEN expression plasmids either alone or in combination and cultured in both hypoxic and normoxic conditions. 2A: Total RNA was obtained and followed with RQ-PCR using primers specific for GLUT-1 and 36B4 (internal control). A significant reduction of GLUT-1 mRNA levels was observed in cells expressing PTEN, FIH-1, or both under normoxic conditions, but interestingly, GLUT-1 mRNA levels were not changed in cells expressing PTEN under hypoxic conditions. Average and standard deviation of three independent experiments were calculated. * Represents p value less than 0.05. 2B: Whole cell lysates from each experimental condition were collected and protein levels of FIH-1 (top panel) and PTEN (middle panel) were examined by Western blot. β-actin was used as a loading control (lower panel).

doi:10.1371/journal.pone.0086102.g002
as shown in the middle panel of Figure 3B. This result, therefore, provides an explanation for the decrease in GLUT-1 levels under hypoxia in the presence of overexpressed FIH-1 alone (Figure 2A). On the other hand, PTEN appears to regulate HIF activity only under normoxia.

FIH-1 decreases VEGF-A mRNA in U87

Apart from GLUT-1, we also examined FIH-1 regulation on vascular endothelial growth factor-A (VEGF-A) expression, another HIF target gene [7,55]. Like GLUT-1, overexpression of FIH-1 in U87 cells down-regulated VEGF-A mRNA levels under normoxic conditions and, importantly, also in hypoxia (Figure 4). Interestingly, the expression levels of GLUT-1 and VEGF-A are different under the HIF-FIH regulation. Glut-1 transcription appears to be more sensitive than VEGF-A. The different responses to HIF may be due to the constitutive structural divergence in their promoter regions harboring the hypoxia response elements.

Inverse correlation of the expression pattern of FIH-1 and VEGF-A in serially transplantable GBM cell lines

In order to understand the significance of the loss of FIH-1 in GBM, we studied the expression levels of FIH-1 and VEGF-A in GBM lines other than U87 as well. We chose a panel of serially transplantable GBM xenografts that were initially established by direct implantation of patient GBM specimens into the flanks of nude mice [46]. These xenograft lines also grow as intracranial xenografts and retain the histopathologic features of their derivative GBM tumors. We examined the relative mRNA levels of VEGF-A and FIH-1 in these GBM xenograft lines, and found that many of the lines expressed high levels of VEGF-A and low levels of FIH-1 (Figures 5A and 5B). In contrast, for those lines with low levels of VEGF-A, elevated FIH-1 levels were detected, indicating an inverse correlation between VEGF-A and FIH-1 expression. Importantly, these contrasting level of VEGF-A and FIH-1 was also in accordance to the association of p300 and HIF-1α observed in the GBM mouse xenograft cell line 6 compared to line 44 (Figure 5C). Interestingly, both the GBM-6 and GBM-44 cell lines have wild type levels of PTEN [46] and expressed similar level of HIF-1α protein (Figure 5C, bottom panel). We further detected FIH-1 expression in GBM-44, GBM-6, -12AT and -14 lines by Immunohistochemistry using the paraffin slides derived from these lines, and there was a significant FIH-1 expression in GBM-44 line but FIH-1 was undetectable in GBM-6, -12AT and -14 lines (Figure 5D). In this respect, only the difference in FIH-1 levels is regulating HIF activity (Figure 5C) and VEGF-A expression (Figure 5A), further confirming the importance of FIH-1 in regulating HIF activity in GBM.

Discussion

In this study, we addressed the consequence of the loss of FIH-1 function in glioblastoma cell lines. A portion of chromosome
10q23-24 is often deleted in glioblastoma, resulting in loss of the tumor suppressor gene PTEN in a subset of up to 40% in primary glioblastoma [40,43,44]. The transcriptional activity of HIF-1α is high in glioblastoma cells [1]. PTEN deletion leads to increased AKT activation and thus to enhanced synthesis of HIF-1α [54]. The FIH-1 gene is located on the 10q arm and is close to PTEN. Therefore, loss of FIH-1 might also be a common occurrence in glioblastoma. “ONCOMINE” data also supports the same notion (figure S1). FIH-1 hydroxylates HIF and thereby inhibits its association with p300 [28,56], which is a co-activator molecule required for HIF function. As such, loss of FIH-1 may account for increased HIF activity in glioblastoma. Therefore, we studied whether ectopically overexpressed FIH-1 could inhibit HIF-mediated gene transcription in the glioblastoma cell line U87 MG.

We compared the role of FIH-1 with that of PTEN in regulating HIF activity. We observed a decrease in GLUT-1 (a HIF-regulated gene) mRNA and protein levels after overexpressing FIH-1 (Figure 1). Importantly, FIH-1 could inhibit GLUT-1 levels even in hypoxia (Figure 2A), which underscores its ability to inhibit HIF-mediated gene transcription in glioblastoma in this condition. In this respect, we would like to point out that although it is a hydroxylase by nature and therefore requires oxygen as one of its substrates, FIH-1 unlike other hydroxylases, has the ability to function even at substantially low oxygen concentrations [35]. It is known that the prolyl hydroxylase, which is required for HIF’s degradation, functions in a much higher oxygen concentration range as compared to FIH-1 [57]. Therefore, FIH-1 could still be in a functionally active state at a certain hypoxic stage that is sufficient for inactivating prolyl hydroxylase and stabilizing the HIF protein. Active FIH-1 in these conditions then interferes with HIF function. In this respect, the absence of FIH-1 activity may be a necessary step for hypoxia-induced HIF function in solid tumors in the advanced stage. On the other hand, we observed that PTEN could inhibit HIF function in normoxia but was unable to influence its activity in hypoxia (Figure 3B). As a result, the loss of FIH-1 seems to be more critical than the loss of PTEN in activating HIF to its full extent in hypoxia. Similar to GLUT-1, overexpression of FIH-1 in U87 cells decreased the levels of VEGF-A mRNA (another HIF mediated gene and important for tumor angiogenesis) in both normoxia and hypoxia (Figure 4) further confirming the importance of FIH-1 in regulating HIF activity in glioblastoma. It is noticed that GLUT-1 and VEGF-A...
A. VEGF-A mRNA level in GBM lines

B. FIH-1 mRNA level in GBM lines

C. Association of p300 with HIF-1α in GBM lines

D. GBM-6 and GBM-14

GBM-12AT and GBM-44
showed different responses to HIF-FIH-1 regulation, which may be due to their intrinsic structural divergence of the hypoxia response element(s) and other cis-elements located in their promoter regions.

We expanded our study from the U87 cell line to a panel of serially transplantable GBM lines established at the Mayo Clinic [46,50]. These GBM lines were initially established by direct implantation of primary patient specimens into the flanks of nude mice. These cell lines can recapitulate the features human glioblastoma better than U87 when they are implanted in mice, therefore gave us the opportunity to address the significance of FIH-1 in a more clinically relevant situation. Moreover, a single cell line study does not address the issues related to tumor heterogeneity and thus is not sufficient to determine the function of a gene in the progression of a solid tumor. We therefore used these serially transplantable GBM lines to determine the relative amounts of FIH-1 and VEGF-A. Our data suggests that the levels of VEGF-A mRNA in those GBM lines are inversely correlated with those of FIH-1 mRNA and therefore validated our results in U87 cell line. When we compared two GBM lines (GBM-6 and GBM-44) having wild-type levels of PTEN [46] but with different levels of FIH-1 (Figure 5D), this data is in parallel with mRNA expression data (Figure 5B) where we observed GBM-44 and -15 only expressed high FIH mRNA. GBM-6 and GBM-44 showed different levels of HIF activity, underscoring the significance of FIH-1 over PTEN in regulating HIF function in GBM (Figure 5A and 5B). Interestingly previous reports on these GBM lines also suggested that the low FIH-1 expressing lines showed rapid tumor progression and poor prognosis. Patients with GBM-6, -12AT and -14 die earlier than patients with GBM-44 and -15 [46]. Mice with orthotopic implantation with GBM-44 survived significantly more than mice with GBM-12AT and-14 lines [58]. These results therefore address the importance of FIH-1 in GBM development and progression, especially in the subset of primary glioblastomas with PTEN wild type.

In summary, this study suggested that loss of FIH-1 may be a crucial event in HIF mediated gene transcription in GBM and thereby important for its progression, but further in-depth studies involving human patient tissues are needed to delineate the function of FIH-1 in the initiation and metastasis of GBM.

Supporting Information

Figure S1 Under-expression of FIH-1 (HIF1AN) in Glioblastoma Multiforme (GBM). The data has been extracted from ONCOMINE database, which compared FIH-1 mRNA levels in normal brain tissues from Epilepsy patients (Class I) and in tumor tissues from GBM patients (Class II). There is a significant reduction of FIH-1 mRNA levels in tumor tissues compared to normal brain tissues.

Author Contributions

Conceived and designed the experiments: J. Li KD. Performed the experiments: EW NP J. Li. Analyzed the data: FL GW. Contributed reagents/materials/analysis tools: MS J. Lau. Wrote the paper: CZ SJ KD. Obtained permission for use of cell line: DM BPO.

References

1. Vordermark D, Brown JM (2003) Evaluation of hypoxia-inducible factor-1alpha (HIF-1alpha) as an intrinsic marker of hypoxia in U87 MG human glioblastoma: in vitro and xenograft studies. International journal of radiation oncology, biology, physics 56:1184–93.
2. Mazure XM, Brahimi-Horn MC, Berta MA, Renzini E, Bilton RL, et al. (2004) HIF-1: master and commander of the hypoxic response. A pharmacological approach to its regulation by siRNAs. Biochemical pharmacology 68:971–80.
3. Greijer AE, van der Groep P, Kemming D, Shvarts A, Semenza GL, et al. (2005) Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). The Journal of pathology 206:291–304.
4. Yeo IJ, Chun YS, Park JW (2004) New anticancer strategies targeting HIF-1. Biochemical pharmacology 68:1061–9.
5. Kang SH, Cho HT, Devi S, Zhang Z, Escuin D, et al. (2006) Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer research 66:11991–7.
6. Brat DJ, Kaur B, Van Meir EG (2003) Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors. Front Biosci 8:d100–16.
7. Kaur B, Tan C, Brat DJ, Post DE, Van Meir EG (2004) Genetic and hypoxia regulation of angiogenesis in gliomas. Journal of neuro-oncology 70:229–43.
8. Evans SM, Jenkins KW, Jenkins WT, Dilling T, Judy KD, et al. (2008) Imaging and analytical methods as applied to the evaluation of vasculature and hypoxia in human brain tumors. Radiation research 170:677–90.
9. Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, et al. (2001) A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided immuno- modulated radiation therapy. International journal of radiation oncology, biology, physics 49:1171–82.
10. Maher EA, Furnari FB, Baichoo RM, Rowitch DH, Louis DN, et al. (2001) Malignant glioma: genetics and biology of a grave matter. Genes & development 15:1311–33.
11. Hill C, Hunter SB, Brat DJ (2003) Genetic markers in glioblastoma: prognostic significance and future therapeutic implications. Advances in anatomic pathology 10:212–7.
12. Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proceedings of the National Academy of Sciences of the United States of America 92:3352–7.
13. Semenza GL, Agani F, Booth G, Foyehe J, Iyer N, et al. (1997) Structural and functional analysis of hypoxia-inducible factor 1. Kidney international 51:535–5.
14. Luo G, Yu GZ, Jain S, Chan WK, Carr KM, et al. (1997) Molecular characterization of the murine Hif-1 alpha locus. Gene expression 6:287–99.
15. Gu YZ, Moran SM, Hogeschens JB, Wartman I, Bradford CA (1998) Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene expression 7:205–13.
16. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EG, et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:273–5.
17. Ivan M, Kondo K, Yang H, Kim W, Valiando J, et al. (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science (New York, NY 292:464–8.
18. Yu F, White SB, Zhao Q, Lee FS (2001) Dynamic, site-specific interaction of hypoxia-inducible factor-1alpha with the von Hippel-Lindau tumor suppressor protein. Cancer research 61:4136–42.
19. Yu F, White SB, Zhao Q, Lee FS (2001) HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proceedings of the National Academy of Sciences of the United States of America 98:3630–5.
20. Kim W, Kaelin WG Jr (2003) The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Current opinion in genetics & development 13:55–60.
21. Safran M, Kaelin WG Jr (2003) HIF hydroxylation and the mammalian oxygen-sensing pathway. The Journal of clinical investigation 111:779–85.
36. Albarosa R, Colombo BM, Roz L, Magnani I, Pollo B, et al. (1996) Deletion on 10p: implications for the human gliaoma cell line U-87. Proceedings of the National Academy of Sciences of the United States of America 93:12869–73.

35. Stolze IP, Tian YM, Appelhoff RJ, Turley H, Wykoff CC, et al. (2004) Genetic analysis of the human glioma cell line U-87: implications for the human glioblastoma cell line U-87. Proceedings of the National Academy of Sciences of the United States of America 93:12869–73.

34. Elkins JM, Hewitson KS, McNeill LA, Seibel JF, Schlemminger I, et al. (2003) Structure and function of the human glioblastoma cell line U-87: implications for the human glioblastoma cell line U-87. Proceedings of the National Academy of Sciences of the United States of America 93:12869–73.

33. Freedman SJ, Sun ZY, Poy F, Kung AL, Livingston DM, et al. (2002) Structural and functional analysis of the human glioblastoma cell line U-87: implications for the human glioblastoma cell line U-87. Proceedings of the National Academy of Sciences of the United States of America 93:12869–73.

32. Hewitson KS, McNeill LA, Riordan MV, Tian YM, Bullock AN, et al. (2002) FIH-1 is a novel protein that interacts with the human glioblastoma cell line U-87: implications for the human glioblastoma cell line U-87. Proceedings of the National Academy of Sciences of the United States of America 93:12869–73.

31. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, et al. (2002) FIH-1 is a novel protein that interacts with the human glioblastoma cell line U-87: implications for the human glioblastoma cell line U-87. Proceedings of the National Academy of Sciences of the United States of America 93:12869–73.

30. Kondo K, Kic J, Nakamura E, Lechpammer M, Kaelin WG Jr (2002) An essential role for the human glioblastoma cell line U-87: implications for the human glioblastoma cell line U-87. Proceedings of the National Academy of Sciences of the United States of America 93:12869–73.

29. Kallio PJ, Okamoto K, O’Brien S, Carrero P, Makino Y, et al. (1998) Signal transduction in the human glioblastoma cell line U-87: implications for the human glioblastoma cell line U-87. Proceedings of the National Academy of Sciences of the United States of America 93:12869–73.

28. Kondo K, Kic J, Nakamura E, Lechpammer M, Kaelin WG Jr (2002) An essential role for the human glioblastoma cell line U-87: implications for the human glioblastoma cell line U-87. Proceedings of the National Academy of Sciences of the United States of America 93:12869–73.

27. Kallio PJ, Okamoto K, O’Brien S, Carrero P, Makino Y, et al. (1998) Signal transduction in the human glioblastoma cell line U-87: implications for the human glioblastoma cell line U-87. Proceedings of the National Academy of Sciences of the United States of America 93:12869–73.

26. Kallio PJ, Okamoto K, O’Brien S, Carrero P, Makino Y, et al. (1998) Signal transduction in the human glioblastoma cell line U-87: implications for the human glioblastoma cell line U-87. Proceedings of the National Academy of Sciences of the United States of America 93:12869–73.

25. Kondo K, Kic J, Nakamura E, Lechpammer M, Kaelin WG Jr (2002) An essential role for the human glioblastoma cell line U-87: implications for the human glioblastoma cell line U-87. Proceedings of the National Academy of Sciences of the United States of America 93:12869–73.

24. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O’Rourke J, et al. (2001) Structure and function of the human glioblastoma cell line U-87: implications for the human glioblastoma cell line U-87. Proceedings of the National Academy of Sciences of the United States of America 93:12869–73.

23. Kaelin WG (2005) Proline hydroxylation and gene expression. Annual review of biochemistry 74:1260–72.

22. Hirota K, Semenza GL (2005) Regulation of hypoxia-inducible factor 1 by prolyl and asparaginyl hydroxylases. Biochemical and biophysical research communications 338:610–6.

21. Linke S, Stojkoski C, Kewley RJ, Booker GW, Whitelaw ML, et al. (2004) Genetic pathways to glioblastomas. Nature genetics 36:1260–7.

20. Sonoda Y, Murakami Y, Tominaga T, Kayama T, Yoshimoto T, et al. (1996) Deletion mapping of chromosome 10 in human glioma. Jpn J Cancer Res 87:637–7.

19. Tohma Y, Gratas C, Bierat W, Perzaud A, Fukuda M, et al. (1998) PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. Journal of neuropathology and experimental neurology 57:684–9.

18. Rhodes DR, Yu J, Shanker K, Deshpande N, Varahambally R, et al. (2004) ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (New York, NY 6:1-6.

17. Sarkaria JN, Carlson BL, Schroeder MA, Grogan P, Brown PD, et al. (2006) Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res 12:2264–71.

16. Datta K, Mondal S, Sinha S, Li J, Wang E, et al. (2005) Role of eloncin-binding domain of von Hippel Lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma. Oncogene 24:7850–8.

15. Sinha S, Dutta S, Datta K, Ghosh AK, Mukhopadhyay D (2009) Von Hippel-Lindau gene product modulates TIS11B expression in renal cell carcinoma: impact on vascular endothelial growth factor expression in hypoxia. The Journal of biological chemistry 284:32610–8.

14. Kaelin WG (2005) Proline hydroxylation and gene expression. Annual review of biochemistry 74:1260–72.

13. Misra S, Fu AA, Mirsa KD, Shergill UM, Leof EB, et al. (2010) Hypoxia-induced phenotypic switch of fibroblasts to myofibroblasts through a matrix metalloproteinase 2/tissue inhibitor of metalloproteinase-mediated pathway: implications for venous neointimal hyperplasia in hemodialysis access. J Vasc Interv Radiol 21:896–902.

12. Carlson BL, Pokorny JL, Schroeder MA, Sarkaria JN (Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery. Current protocols in pharmacology/editorial board, S.J. Enna (editor-in-chief) … [et al. Chapter 14:Unit 14 16.

11. Duerr EM, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, et al. (1998) PTEN mutations in gliomas and glioneuronal tumors. Oncogene 16:2259–64.

10. Ohgaki H (2005) Genetic pathways to glioblastomas. Neuropathology 25:1–7.

9. Wen S, Stodarow J, Myers MP, Su JD, Wigler MH, et al. (2004) PTEN controls tumor-induced angiogenesis. Proceedings of the National Academy of Sciences of the United States of America 99:16264–6.

8. Tohma Y, Gratas C, Bierat W, Perzaud A, Fukuda M, et al. (1998) PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. Journal of neuropathology and experimental neurology 57:684–9.

7. Sonoda Y, Murakami Y, Tominaga T, Kayama T, Yoshimoto T, et al. (1996) Deletion mapping of chromosome 10 in human glioma. Jpn J Cancer Res 87:637–7.

6. Steck PA, Peshouse MA, Jasser SA, Yung WK, Lin H, et al. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature genetics 15:356–62.

5. Fujisawa H, Reis RM, Nakamura M, Colella S, Yonekawa Y, et al. (2000) Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Laboratory investigation; a journal of technical methods and pathology 80:65–72.

4. Tohma Y, Gratas C, Bierat W, Perzaud A, Fukuda M, et al. (1998) PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. Journal of neuropathology and experimental neurology 57:684–9.

3. Sonoda Y, Murakami Y, Tominaga T, Kayama T, Yoshimoto T, et al. (1996) Deletion mapping of chromosome 10 in human glioma. Jpn J Cancer Res 87:637–7.

2. Steck PA, Peshouse MA, Jasser SA, Yung WK, Lin H, et al. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature genetics 15:356–62.

1. Fujisawa H, Reis RM, Nakamura M, Colella S, Yonekawa Y, et al. (2000) Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Laboratory investigation; a journal of technical methods and pathology 80:65–72.